Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Clinical data near for Alzheimer’s antibodies from Roche and Lilly, while Cortexyme and Biohaven test small molecules.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.